Prevalence and socio-economic aspects of chronic kidney disease.

The incidence and prevalence of end-stage renal disease (ESRD) are rising in Europe, the USA, and Japan. Prevalence is rising more steeply than incidence, due mostly to improved efficiency of treatment -patients are surviving longer. Hypertension and diabetes, the main causes of progression from chronic kidney disease (CKD) to ESRD, are becoming more frequent in the general population and make a large contribution to the rising incidence of ESRD. More effective therapies for other conditions have introduced new complications for patients with CKD, thereby also increasing the incidence of ESRD. Increased survival in the general population is reflected in the greater number of elderly people requiring care for ESRD. ESRD is a great economic burden and one that will increase as the incidence and prevalence of the disease increase. This needs to be considered when planning treatment. Prevention and early treatment of hypertension and diabetes will have the greatest impact on the future prevalence of ESRD and the costs associated with its treatment.

[1]  [Kidney diseases in diabetes in children]. , 1963, La Semana medica.

[2]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[3]  R. Zietse,et al.  Renal insufficiency after heart transplantation: a case-control study. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  W. Rathmann,et al.  Epidemiologie und Verlauf des Diabetes mellitus in Deutschland , 2004 .

[5]  P. Bennett,et al.  Kidney Diseases in Diabetes , 1996 .

[6]  H. Valkenburg,et al.  Prevalence and Determinants of Glucose Intolerance in a Dutch Caucasian Population: The Hoorn Study , 1995, Diabetes Care.

[7]  G. Gallus,et al.  An Italian population-based study of the prevalence of diabetes: some methodological aspects. , 1993, Diabete & metabolisme.

[8]  K. Asplund,et al.  Diabetes as a risk factor for myocardial infarction: population and gender perspectives , 1997, Journal of internal medicine.

[9]  M. Zeier,et al.  [Incidence and clinical characteristics of renal insufficiency in diabetic patients]. , 2001, Deutsche medizinische Wochenschrift.

[10]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[11]  G. Grateau,et al.  Amylose rénale secondaire et mucoviscidose , 1998 .

[12]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[13]  F. Waagstein,et al.  Predictors and evolution of renal function during 9 years following heart transplantation. , 2000, Journal of the American Society of Nephrology : JASN.